Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (401-410 of 446) with videos related to

Pageof 45
Sort By:
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
American Journal of Hematology|July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantationCihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology|June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myelomaToshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Leukemia|February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.
Blood Cancer Journal|February 27, 2020
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosisAngela Dispenzieri, Bonnie Arendt, Surendra Dasari, et al.
Pageof 45

Showing results (401-410 of 446) with videos related to

Sort By:
Pageof 45
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
American Journal of Hematology|July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantationCihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology|June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myelomaToshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Leukemia|February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.
Blood Cancer Journal|February 27, 2020
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosisAngela Dispenzieri, Bonnie Arendt, Surendra Dasari, et al.
Pageof 45